Compared with empagliflozin (Jardiance; Boehringer Ingelheim/Eli ... a risk that was elevated when the 5-mg dose was used. “These findings reinforce the use of dapagliflozin 10 mg, or other SGLT2 ...

Researchers analyzed concentrations of microplastics in 91 brain tissue samples collected during autopsies in 2016 and 2024. The samples were from the frontal cortex, the brain region above and behind ...

Compared with people who had type 2 diabetes treated with empagliflozin (Jardiance ... the 10-mg for cardiovascular risk reduction -- the latter being what had been studied in the drug's ...

Let’s dive into the details with these 10 images. Revealed at the Bharat Mobility Global Expo 2025 (aka Auto Expo 2025), this ultra-premium electric MPV is the second addition to MG’s elite ...

The MG Majestor made its grand debut at Auto Expo 2025, as another entrant in the Indian SUV market. We break down the key design elements and expected features of the Majestor in our image gallery.

Eli Lilly and Boehringer Ingelheim's blockbuster diabetes drug Jardiance (empagliflozin) has been granted approval by the US Food and Drug Administration (FDA) for a wider range of heart failure ...

Nonincretin revenue climbed 20% year-over-year fueled by diabetes drug Jardiance ($1.2 billion with 50% growth) and breast cancer therapy Verzenio ($1.6 billion with 36% growth). However Type 2 ...

and sales of diabetes drug Jardiance increased 50% to $1.19 billion. Zepbound sales reached $1.91 billion, up from $175.8 million a year ago. Trulicity sales fell 25% to $1.25 billion. Guidance ...

A year ago Eli Lilly and Boehringer Ingelheim produced results which showed their oral SGLT2 inhibitor drug Jardiance (empagliflozin ... semaglutide 0.5 mg and 1.0 mg significantly reduced ...

Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Nonincretin revenue climbed 20% year-over-year fueled by diabetes drug Jardiance ($1.2 billion with 50% growth) and breast cancer therapy Verzenio ($1.6 billion with 36% growth). However Type 2 ...